Naviter Wealth LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 11.0% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 21,466 shares of the company's stock after selling 2,648 shares during the quarter. Naviter Wealth LLC's holdings in Johnson & Johnson were worth $3,279,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in the business. Brighton Jones LLC increased its stake in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after buying an additional 6,332 shares during the period. Wealth Group Ltd. purchased a new position in shares of Johnson & Johnson in the first quarter worth $218,000. GAMMA Investing LLC increased its stake in shares of Johnson & Johnson by 48.0% in the first quarter. GAMMA Investing LLC now owns 43,508 shares of the company's stock worth $7,215,000 after buying an additional 14,118 shares during the period. Wealth Enhancement Advisory Services LLC increased its stake in shares of Johnson & Johnson by 6.7% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 1,698,831 shares of the company's stock worth $281,734,000 after buying an additional 107,009 shares during the period. Finally, Optivise Advisory Services LLC increased its stake in shares of Johnson & Johnson by 8.1% in the first quarter. Optivise Advisory Services LLC now owns 2,265 shares of the company's stock worth $376,000 after buying an additional 169 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Stock Performance
Shares of JNJ stock opened at $191.79 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $194.40. The stock has a market cap of $461.90 billion, a PE ratio of 18.51, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company's fifty day moving average price is $180.09 and its 200-day moving average price is $164.52.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The firm had revenue of $24.02 billion for the quarter. On average, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson's payout ratio is 55.61%.
Analyst Ratings Changes
Several brokerages recently commented on JNJ. The Goldman Sachs Group lifted their target price on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a "buy" rating in a research note on Thursday, October 9th. Sanford C. Bernstein lifted their price target on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a "market perform" rating in a report on Monday, October 6th. Raymond James Financial lifted their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an "outperform" rating in a report on Wednesday. Citigroup lifted their price target on shares of Johnson & Johnson from $213.00 to $215.00 and gave the company a "buy" rating in a report on Wednesday. Finally, Guggenheim upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price target for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $199.59.
Read Our Latest Stock Analysis on JNJ
Insider Activity at Johnson & Johnson
In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.16% of the company's stock.
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
